TABLE 2.
Baseline clinical characteristics: randomized crossover study1
| Characteristic | Juice first (n = 22) | Placebo first (n = 22) | P2 |
| Age (y) | 61 ± 113 | 63 ± 9 | 0.44 |
| Male sex [n (%)] | 15 (68) | 15 (68) | 1.00 |
| Black race [n (%)] | 4 (18) | 6 (27) | 0.47 |
| History of hypertension [n (%)] | 17 (77) | 14 (64) | 0.32 |
| History of diabetes mellitus [n (%)] | 12 (55) | 8 (36) | 0.23 |
| History of smoking [n (%)] | 15 (68) | 15 (68) | 1.00 |
| Lipid-lowering therapy [n (%)] | 21 (95) | 21 (95) | 1.00 |
| Aspirin therapy [n (%)] | 17 (77) | 18 (82) | 0.71 |
| Clopidogrel therapy [n (%)] | 8 (36) | 5 (23) | 0.32 |
| ACE inhibitor or ARB therapy [n (%)] | 11 (50) | 11 (50) | 1.00 |
| BMI (kg/m2) | 30 ± 5 | 29 ± 4 | 0.65 |
| Total cholesterol (mg/dL) | 161 ± 46 | 152 ± 34 | 0.45 |
| LDL cholesterol (mg/dL) | 92 ± 38 | 84 ± 30 | 0.45 |
| HDL cholesterol (mg/dL) | 40 ± 11 | 43 ± 9 | 0.40 |
| Triglycerides (mg/dL) | 144 ± 56 | 126 ± 59 | 0.29 |
| Fasting glucose (g/dL) | 130 ± 47 | 115 ± 30 | 0.22 |
| Fasting insulin (μIU/dL) | 9.1 ± 5.9 | 9.4 ± 8.1 | 0.92 |
1
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
2
P value for unpaired t test or chi-square test as appropriate.
3
Mean ± SD (all such values).